Login / Signup

Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease.

Takashi InoueShokei MurakamiKenji MatsumotoAkio Matsuda
Published in: Pediatric rheumatology online journal (2020)
A corticosteroid can effectively inhibit the release of HMGB1 and IL-1α, which may be involved in IVIG resistance in KD. Since high-dose IgG does not have such beneficial anti-cytotoxic effects, adding a corticosteroid to standard IVIG therapy may help prevent the progression of IVIG resistance in KD.
Keyphrases
  • combination therapy
  • coronary artery
  • high dose
  • endothelial cells
  • low dose
  • pulmonary artery
  • stem cell transplantation
  • pulmonary hypertension
  • bone marrow
  • mesenchymal stem cells
  • vascular endothelial growth factor